logo
Ozempic and Wegovy: The pros and cons, explained

Ozempic and Wegovy: The pros and cons, explained

RNZ Newsa day ago
A man holds a syringe with the drug Ozempic for the treatment of type 2 diabetes.
Photo:
ROBERTO PFEIL / AFP
Earlier this week semaglutide drugs Ozempic and Wegovy
were made available for prescription in New Zealand
.
Semaglutide originally arrived on the market in the US in 2017 as a diabetes medication, but has quickly been tied to
extreme weight loss
.
Wegovy can be prescribed to people over the age of 12, but many of the 65 percent of New Zealanders who are overweight or obese will have trouble affording it, with an estimated price of $500 a month.
The drugs have transformed our ability to manage obesity and type 2 diabetes, and have shown potential for a wide range of conditions such as Alzheimer's, addiction and depression.
But there are clouds to go along with the silver linings - such as potential vision loss.
"This condition, it occurs when there's insufficient blood flow to the nerves connecting the eye to the brain, and this leads to damage," US-based health reporter for
New Scientist
, Grace Wade, told RNZ's
Sunday Morning
. The specific condition was non-arteritic anterior ischemic optic neuropathy.
"That can cause this sudden and permanent vision loss, usually in just one eye. Now, I should be clear this isn't total vision loss, at least usually - it's more like cloudiness, stuff like that."
People using semaglutides to treat diabetes were 4.3 times more likely to develop this condition, and those using it for weight loss 7.6 times, as people using other types of diabetes medications, a 2024 study found (Wade wrote about it in
New Scientist
here
).
The drugs work by suppressing appetite, which typically leads to weight loss as people consume fewer calories. But the weight lost was not always beneficial, Wade said.
"It leads the body to break down fat, muscle and actually even bone for nutrients, and that's why… some research has found that upwards of 40 percent of the weight loss seen with these medications is due to loss of muscle mass… that makes it really important that people prioritise exercise when taking these drugs because if you don't use your muscle, you're more likely to lose it."
Getting into the exercise habit was also important since one day, most people on Ozempic or Wegovy will stop taking it - putting themselves at risk of putting the weight back on if they were not regularly moving.
Then there is 'Ozempic face'.
"I don't think this is a clinical term yet, but it's something that's popped up a lot in social media," Wade said.
"People who are taking these medications start developing... a sunken or hollowed out appearance, which can exacerbate fine lines and wrinkles, make their skin look a little more saggy.
"It isn't clear exactly how common this is… but it probably has to do with just weight loss, right? If you're losing weight, as much as some people would want to target their weight loss to certain areas of their body, we can't really do that. So, you know, any sort of overall weight loss is also gonna cause a loss of fat in your face."
There were also side effects for some, including constantly needing to go to the toilet, feeling bloated, belching, constipation, heartburn, fever, upset stomach - the list,
collected here by the Mayo Clinic, goes on
.
And nearly half of people who try it make it through a three-month course, one study found.
Wade also mentioned a lot of people taking semaglutide for diabetes or Alzheimer's prevention might be older and "frail", so not able to lose weight.
"Drug developers are actually working to develop new drugs that have similar effects as these weight loss medications, but without the weight loss."
One unexpected benefit of semaglutide was its apparent effect on not just calorie consumption, but use of addictive substances, such as alcohol and nicotine.
"We aren't exactly sure why that is, but it appears to be with how these medications affect brain activity.
"So these drugs curb cravings for alcohol similar to how they curb cravings for food, right? And that probably has to do with their impact on brain regions involved in reward processing and craving…
"A study of more than half-a-million people with a history of opioid use disorders showed that those who took Ozempic or similar [medications] had significantly lower rates of opioid overdose than those who didn't.
Grace Wade.
Photo:
New Scientist
"Other studies have shown similar effects in people with cannabis use disorder, cigarette smokers and alcoholism."
Scientists did not expect this effect, calling it an "unintended consequence".
The drugs have also shown promise in reducing heart attacks and strokes, improving fertility, treating pain, improving mental health, lower the risk of kidney failure and slowing cognitive decline.
"I've never encountered a group of drugs like this," Wade said. "That's what makes these drugs so remarkable, because most medications can only treat one or two conditions, right?"
She said it was likely that weight loss was playing a role - as it frequently does in health - but "it doesn't seem to be the only [reason]".
But there is still a lot of research to be done, she said, before we all start taking it.
"Let's unravel how they can treat all of these conditions before we jump the gun and start suggesting we, you know, maybe put it in everyone's water or something."
Sign up for Ngā Pitopito Kōrero, a daily newsletter
curated by our editors and delivered straight to your inbox every weekday.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Getting insight into how women with rheumatoid arthritis experience perimenopause
Getting insight into how women with rheumatoid arthritis experience perimenopause

RNZ News

time2 hours ago

  • RNZ News

Getting insight into how women with rheumatoid arthritis experience perimenopause

Rheumatoid arthritis, also called RA, is an autoimmune disease that causes inflammation, pain and swelling in the joints. It most often develops between the ages of 25 and 50, and affects more women than men. A research project is getting underway in the hopes of bridging the gap on how women with RA experience perimenopause. Click here if you'd like to take part in Jo's research. Jo Miller, a Massey University master's student, is researching how women with rheumatoid arthritis experience perimenopause. Photo: SUPPLIED/Jo Miller

Watch live: First public hearings into New Zealand's Covid-19 response begin
Watch live: First public hearings into New Zealand's Covid-19 response begin

RNZ News

time6 hours ago

  • RNZ News

Watch live: First public hearings into New Zealand's Covid-19 response begin

The first public hearings into New Zealand's Covid response get under way on Monday - with a focus on lockdowns and vaccines. The Royal Commission of Inquiry into Covid-19 is looking into the government's response to the pandemic and its effects. It is the first time submissions will be heard publicly, with the sessions livestreamed. You can watch it at the top of this page and follow updates in our live blog above. This week's hearings particularly concentrate on the impact of the extended lockdown in Auckland and Northland in 2021 and on vaccine mandates and safety. In a minute issued on the Inquiry's website chair Grant Illingworth KC said that would include the effect on "social division and isolation, health and education, and business activity. "We will also hear from experts about the key decisions and their consequences, and lessons to be learned from what happened." The hearings would be in secure hearing rooms, with commissioners, witnesses, lawyers and media present. There was no provision for public attendance beyond those submitting but the live streams would run and be available as recordings as well, the minute said. Witnesses would be questioned by lawyers helping the inquiry, and commissioners could ask questions. A second public hearing was due next month in Wellington. That was to hear from key decisions makers who "led and informed" the government's response to the pandemic. This Royal Commission was set up under the previous Labour government, but its brief was expanded under the current government, with Illingworth taking the chairing role. A report from the first phase was delivered last year. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

Workplace mental health support- do employers understand obligations?
Workplace mental health support- do employers understand obligations?

RNZ News

time6 hours ago

  • RNZ News

Workplace mental health support- do employers understand obligations?

Generic, stressed worker. Photo: RNZ / Rebekah Parsons-King Xero has confirmed it is dropping the employee assistance programme it offered free to businesses that use its software. Those customers could use it to provide mental health support to their own staff, as an employee assistance scheme - or EAP. When its offering winds up at the end of the month, Xero customers will still have the option to access professional wellbeing support for their employees, with the same international EAP provider, but they'll have to pay. Businesses have a level of responsibility for staff physical and mental health, under the 2015 Health and Safety at work Act. But do employers understand their obligations under the law? Kathryn speaks to Peter Siminovich, chief executive of Mind Compass, which is contracted by the Employers and Manufacturers Association to train its members on stress and wellness management in their businesses. She also speaks with Council of Trade Unions Legal Officer, Gayaal Iddamalgoda.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store